Levamisole in prevention of recurrent upper-respiratory-tract infections in children.
70 children with chronically relapsing mild-to-severe upper-respiratory-tract infections during autumn and winter participated in a six month double-blind placebo-controlled trial: 38 of them received about 1-25 mg/kg of levamisole twice daily for two consecutive days every week, the others were given placebo. During each of the three trial periods, levamisole proved superior to placebo in that it significantly reduced the number, the duration, and the severity of the infections. Moreover, in the group treated with the higher dose (i.e. greater than 2-5 mg/kg/day), the superiority of levamisole to placebo was much more clear-cut. No drug-related side-effects were reported.
D000293:Adolescent; D001530:Belgium; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007978:Levamisole / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D010919:Placebos; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000453:epidemiology / Q000517:prevention & control*; D012621:Seasons; D013997:Time Factors
D010919:Placebos; D007978:Levamisole